Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. on June 11, 2025, with the earliest event reported on that date. The filing details a corporate action to effect a reverse stock split and confirms the company's regained compliance with Nasdaq listing requirements.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or margin data. However, it details significant changes to the company's capital structure:
- Reverse Stock Split Ratio: 1-for-6.
- Outstanding Shares: Reduced from 3,280,000 to approximately 546,667.
- Authorized Common Shares: Reduced from 50,000,000 to 8,333,333.
- Authorized Preferred Shares: Reduced from 416,667 to 69,444.
- New CUSIP: 04301G607.
- Warrant Adjustment: Existing warrants from the October 2020 financing (exercise price $0.75) are adjusted to an exercise price of $4.50 per post-split share.
Material Changes Versus Prior Period
The primary material change is the reduction in share count and the adjustment of derivative securities to maintain economic equivalence following the reverse split. Additionally, the company has transitioned from a non-compliant status regarding Nasdaq's minimum bid price requirement to a compliant status.
Guidance, Outlook, and Management Commentary
Management Commentary: The reverse split is intended to improve the marketability and liquidity of the common stock and to regain compliance with Nasdaq continued listing requirements.
Regulatory Status: On June 13, 2025, Nasdaq confirmed the company regained compliance with Listing Rule 5550(a)(2) (minimum bid price of $1.00). This determination was based on the closing bid price being at or above $1.00 for eleven consecutive business days (May 29 through June 12, 2025) prior to the split.
Unusual Items: No fractional shares will be issued; holders entitled to fractional shares will receive one whole share instead.
Investor Verification Checklist
- Verify the effective time of the reverse split (12:01 a.m. Eastern Time, June 13, 2025).
- Confirm the new CUSIP number (04301G607) for trading purposes.
- Review the adjusted exercise price of outstanding warrants ($4.50) and their maturity date (October 13, 2025).
- Monitor the stock price post-split to ensure continued compliance with Nasdaq listing standards.
- Check the company's latest 10-K or 10-Q for financial performance metrics, as this 8-K contains no financial statements.